For the year ending 2025-12-31, RNAC made $2,797K in revenue. -$130,257K in net income. Net profit margin of -4657.03%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenues | 2,797 | |||
| Research and development | 58,034 | |||
| General and administrative | 31,468 | |||
| Impairment of indefinite-lived intangible and long-lived assets | 56,700 | |||
| Total operating expenses | 146,202 | |||
| Operating loss | -143,405 | |||
| Interest income | 6,579 | |||
| Gain on change in fair value of warrant liabilities | -3,695 | |||
| Loss on change in fair value of contingent value right liability | 4,354 | |||
| Loss on change in fair value of forward contract liabilities | 0 | |||
| Other (expense) income, net | -2,010 | |||
| Total other income (expense), net | 3,910 | |||
| Loss before income taxes | -139,495 | |||
| Income tax benefit (expense) | -9,193 | |||
| Net loss | -130,302 | |||
| Foreign currency translation adjustment | 45 | |||
| Total comprehensive loss | -130,257 | |||
| Basic EPS | -5.02 | |||
| Diluted EPS | -5.02 | |||
| Basic Average Shares | 25,973,329 | |||
| Diluted Average Shares | 25,973,329 | |||
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)